Ono acquires global rights to Chordia's lymphoma candidate

15 December 2020
ono-big

Japanese firms Ono Pharmaceutical (TYO: 4528) and Chordia Therapeutics have agreed a licensing deal on CTX-177, the latter company’s MALT1 inhibitor and its related compounds.

Under the terms of the agreement, Ono will have exclusive global rights to develop, manufacture and commercialize CTX-177 and its related compounds.

Ono will pay to Chordia 800 million yen ($7.7 million) as an upfront payment and 2.5 billion yen at the time of starting a Phase I clinical study, as one of the pre-defined development milestones.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology